ImmunoPrecise Antibodies provides update on dengue vaccine breakthrough

ImmunoPrecise provided an update following its June 5, press release. This new release details the downstream validation of the epitope identified in that initial announcement-demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. “This is a major step forward,” said Jennifer Bath, CEO of ImmunoPrecise. “Our AI technology not only found a new target for a universal dengue vaccine, but we’ve now shown it’s safe and can trigger the right immune response. With this validation, we’re excited to move ahead and advance this candidate toward the next stages of vaccine development.” Following the recent discovery of a unique “Achilles’ heel” shared by all four types of dengue virus, ImmunoPrecise has confirmed-using its patented Hyft technology and LENSai Immunogenicity Screener-that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine.